| Phenotype | Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 230 had atopic march, 227 had persistent eczema and wheeze, 380 had persistent eczema with late-onset rhinitis, 429 had persistent wheeze with late-onset rhinitis, 599 had transient wheeze, 1089 had eczema only and 791 had rhinitis only. |
| Sample Ancestry | European, NR |
| Additional Ancestry Description | European = 6345, NR = 897 |
| Total number | 7,242 individuals |
| Detailed numbers |
3,745 cases (51.71%)
3,497 controls
51.45% Male samples
|
| Number of Cohort(s) | 2 |
Cohort Short Name
|
Cohort Full Name
|
Previous/other/additional names (e.g. sub-cohorts)
|
|---|---|---|
| ALSPAC | Avon Longitudinal Study of Parents and Children | — |
| MAAS | Manchester Asthma and Allergy Study | — |
Possible sample overlap (up to 88%) between this dataset and the dataset used to source variants for the PRS.